Cited 3 times in
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조재호 | - |
dc.contributor.author | 최서희 | - |
dc.date.accessioned | 2023-03-03T02:54:16Z | - |
dc.date.available | 2023-03-03T02:54:16Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192924 | - |
dc.description.abstract | Purpose: This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer. Materials and methods: Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters. Results: When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%. Conclusion: A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Hormones | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoplasm Recurrence, Local / surgery | - |
dc.subject.MESH | Prostate-Specific Antigen* | - |
dc.subject.MESH | Prostatectomy | - |
dc.subject.MESH | Prostatic Neoplasms* / pathology | - |
dc.subject.MESH | Prostatic Neoplasms* / radiotherapy | - |
dc.subject.MESH | Prostatic Neoplasms* / surgery | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Salvage Therapy | - |
dc.title | Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Sung Uk Lee | - |
dc.contributor.googleauthor | Jae-Sung Kim | - |
dc.contributor.googleauthor | Young Seok Kim | - |
dc.contributor.googleauthor | Jaeho Cho | - |
dc.contributor.googleauthor | Seo Hee Choi | - |
dc.contributor.googleauthor | Taek-Keun Nam | - |
dc.contributor.googleauthor | Song Mi Jeong | - |
dc.contributor.googleauthor | Youngkyong Kim | - |
dc.contributor.googleauthor | Youngmin Choi | - |
dc.contributor.googleauthor | Dong Eun Lee | - |
dc.contributor.googleauthor | Won Park | - |
dc.contributor.googleauthor | Kwan Ho Cho | - |
dc.identifier.doi | 10.4143/crt.2021.985 | - |
dc.contributor.localId | A03901 | - |
dc.contributor.localId | A04867 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 34883554 | - |
dc.contributor.alternativeName | Cho, Jae Ho | - |
dc.contributor.affiliatedAuthor | 조재호 | - |
dc.contributor.affiliatedAuthor | 최서희 | - |
dc.citation.volume | 54 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1191 | - |
dc.citation.endPage | 1199 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.54(4) : 1191-1199, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.